Janux Therapeutics, Inc.JANX
What Janux Therapeutics, Inc. does.
Unless the context otherwise requires, the terms “Janux Therapeutics,” “Janux,” “we,” “us,” “our” and similar references in this Annual Report on Form 10-K refer to Janux Therapeutics, Inc.
We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. The goal of our TRACTr and TRACIr platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming the liabilities associated with prior generations of TCEs. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) on-target healthy tissue immune activation that contributes to cytokine release syndrome (CRS) and healthy tissue toxicity and (ii) poor pharmacokinetics (PK) leading to short half-life.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Net income | -$6.8M | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| Free cash flow | -$4.4M | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
More on JANX.
- Janux Therapeutics, Inc. summary
- Janux Therapeutics, Inc. financial statements
- Janux Therapeutics, Inc. key metrics
- Janux Therapeutics, Inc. health scores and style box
- Janux Therapeutics, Inc. earnings
- Janux Therapeutics, Inc. dividends
- Janux Therapeutics, Inc. valuation
- Janux Therapeutics, Inc. ownership and insiders
- Janux Therapeutics, Inc. peers
Figures from Janux Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.